Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TENAX THERAPEUTICS, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,274 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Purchase · Acquired 53,000 · Balance 55,274 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 30,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2035-07-01 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 80,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 100,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3,200.00 · Expires 2031-06-10 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 4 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Biohaven Pharmaceutical Holding Co Ltd.
Report date December 31, 2021 · Filed February 11, 2022
Section 16 reporting ended · disclosed 2022-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-11-30 transaction · row 28
4 source rows · reconciled sequenceRow 1 · 2021-03-08 · Gift · Disposed 210,000 · Balance 610,647 Row 12 · 2021-05-18 · Gift · Disposed 113,912 · Balance 496,735 Row 26 · 2021-11-22 · Gift · Disposed 491,260 · Balance 5,475 Row 28 · 2021-11-30 · Gift · Disposed 5,475 · Balance 0 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 140,000 |
Reported balance
After 2021-03-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-03-08 · Gift · Acquired 140,000 · Balance 140,000 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 84 |
Reported balance
After 2021-03-18 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2021-03-18 · Gift · Disposed 139,916 · Balance 84 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 132,985 |
Reported balance
After 2021-03-24 transaction · row 11
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 11 · 2021-03-24 · Gift · Acquired 132,901 · Balance 132,985 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 246,897 |
Reported balance
After 2021-05-18 transaction · row 13
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 13 · 2021-05-18 · Gift · Acquired 113,912 · Balance 246,897 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 278,437 |
Reported balance
After 2021-05-18 transaction · row 14
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 14 · 2021-05-18 · Gift · Acquired 31,540 · Balance 278,437 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 108,437 |
Reported balance
After 2021-05-21 transaction · row 18
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 18 · 2021-05-21 · Other · Disposed 170,000 · Balance 108,437 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 129,237 |
Reported balance
After 2021-05-21 transaction · row 19
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 19 · 2021-05-21 · Gift · Acquired 20,800 · Balance 129,237 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 136,252 |
Reported balance
After 2021-10-14 transaction · row 23
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 23 · 2021-10-14 · Gift · Acquired 7,015 · Balance 136,252 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 627,512 |
Reported balance
After 2021-11-22 transaction · row 27
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 27 · 2021-11-22 · Gift · Acquired 491,260 · Balance 627,512 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 632,987 |
Reported balance
After 2021-11-30 transaction · row 29
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 29 · 2021-11-30 · Gift · Acquired 5,475 · Balance 632,987 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 70,000 |
Reported balance
After 2021-03-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-03-08 · Gift · Acquired 70,000 · Balance 70,000 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 9,225 |
Reported balance
After 2021-03-16 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-03-16 · Gift · Disposed 60,775 · Balance 9,225 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 31,540 |
Reported balance
After 2021-03-22 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2021-03-22 · Gift · Acquired 22,315 · Balance 31,540 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 52,340 |
Reported balance
After 2021-05-18 transaction · row 16
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 16 · 2021-05-18 · Gift · Acquired 20,800 · Balance 52,340 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 20,800 |
Reported balance
After 2021-05-18 transaction · row 17
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 17 · 2021-05-18 · Gift · Disposed 31,540 · Balance 20,800 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 0 |
Reported balance
After 2021-05-21 transaction · row 21
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 21 · 2021-05-21 · Gift · Disposed 20,800 · Balance 0 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 7,342 |
Reported balance
After 2021-10-14 transaction · row 25
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 25 · 2021-10-14 · Gift · Acquired 7,342 · Balance 7,342 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 60,775 |
Reported balance
After 2021-03-16 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-03-16 · Gift · Acquired 60,775 · Balance 60,775 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 38,460 |
Reported balance
After 2021-03-22 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2021-03-22 · Gift · Disposed 22,315 · Balance 38,460 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 17,660 |
Reported balance
After 2021-05-18 transaction · row 15
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 15 · 2021-05-18 · Gift · Disposed 20,800 · Balance 17,660 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 187,660 |
Reported balance
After 2021-05-21 transaction · row 20
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 20 · 2021-05-21 · Other · Acquired 170,000 · Balance 187,660 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 180,318 |
Reported balance
After 2021-10-14 transaction · row 24
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 24 · 2021-10-14 · Gift · Disposed 7,342 · Balance 180,318 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan 2021 Trust | 139,916 |
Reported balance
After 2021-03-18 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2021-03-18 · Gift · Acquired 139,916 · Balance 139,916 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan 2021 Trust | 7,015 |
Reported balance
After 2021-03-24 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2021-03-24 · Gift · Disposed 132,901 · Balance 7,015 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan 2021 Trust | 0 |
Reported balance
After 2021-10-14 transaction · row 22
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 22 · 2021-10-14 · Gift · Disposed 7,015 · Balance 0 |
| Common SharesSEC Table I · non-derivative | IndirectBy the Declan Doogan 2014 Trust | 676,002 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 30
Holding and transaction disclosures are not merged.
1 source rowRow 30 · Balance 676,002 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 01:30 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 53,000 | $1.92 | $101,760.00 |
DisclosureSEC source: 0001193125-26-394831 · ownership.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,274 Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 01:03 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001704234-26-000001 · primary_doc.xml · derivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-01-09 Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 12:12 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001654954-25-007737 · section16.xml · derivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-07-01 Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 00:58 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001654954-24-015473 · section16.xml · derivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-10 Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 20:24 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GiftCommon Stock | 567,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-011198 · section16.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,637,871 F1 · kind: Issuer's shares held in a grantor retained annuity trust (the "GRAT") were distributed to the reporting person upon termination of the GRAT and in satisfaction of an annuity due to the reporting person. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 20:24 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GiftCommon Stock | 567,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-011198 · section16.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Declan Doogan 2021 GRAT DTD 03-04-2021 Disclosed balance after: 0 F1 · kind: Issuer's shares held in a grantor retained annuity trust (the "GRAT") were distributed to the reporting person upon termination of the GRAT and in satisfaction of an annuity due to the reporting person. F2 · ownership.nature: The reporting person's wife, Dorothy Doogan, is the trustee of the GRAT. Read SEC document |
| June 09, 2022 Filed Jun 11, 2022 01:08 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001654954-22-008235 · section16.xml · derivative · entry 3 Doogan Declan · CIK 0001704234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-09 Read SEC document |
| November 30, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 5,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 29 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 632,987 Read SEC document |
| November 30, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 5,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 28 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 19:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 11,499 | $113.25 | $1,302,315.80 |
DisclosureSEC source: 0001562180-21-007370 · primarydocument.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,648 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.92 - $113.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 19:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 13,026 | $112.40 | $1,464,117.19 |
DisclosureSEC source: 0001562180-21-007370 · primarydocument.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,147 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.92 - $112.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 491,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 27 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 627,512 Read SEC document |
| November 22, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 491,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 26 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,475 Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to buy) · Derivative | 18,000 | $0.00 Strike: $47.10 | $0.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · derivative · entry 18 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2030-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to buy) · Derivative | 30,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · derivative · entry 17 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on April 6, 2017, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to buy) · Derivative | 18,000 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · derivative · entry 16 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to buy) · Derivative | 18,000 | $0.00 Strike: $28.76 | $0.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · derivative · entry 15 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2028-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to buy) · Derivative | 50,000 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · derivative · entry 14 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on December 15, 2016, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to buy) · Derivative | 175,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · derivative · entry 13 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 175,000 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on October 23, 2015, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to buy) · Derivative | 250,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · derivative · entry 12 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 250,000 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on November 26, 2014, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 7,073 | $117.87 | $833,711.49 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 10 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,173 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.33 - $118.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 18,230 | $116.69 | $2,127,173.02 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 9 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,246 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.32 - $117.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 12,437 | $115.90 | $1,441,500.54 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 8 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,476 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 - $116.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 18,000 | $47.10 | $847,800.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 7 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 30,000 | $10.82 | $324,600.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 6 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 18,000 | $61.76 | $1,111,680.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 5 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 18,000 | $28.76 | $517,680.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 4 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 50,000 | $9.29 | $464,500.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 3 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 175,000 | $5.60 | $980,000.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 19:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 250,000 | $0.61 | $152,500.00 |
DisclosureSEC source: 0001562180-21-007138 · primarydocument.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 7,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 25 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dorothy Doogan Revocable Trust Disclosed balance after: 7,342 Read SEC document |
| October 14, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 7,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 24 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dorothy Doogan 2020 Trust Disclosed balance after: 180,318 Read SEC document |
| October 14, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 7,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 23 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 136,252 Read SEC document |
| October 14, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 7,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 22 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan 2021 Trust Disclosed balance after: 0 Read SEC document |
| June 30, 2021 Filed Aug 11, 2021 20:30 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GiftCommon Stock | 567,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-008766 · section16.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,502,129 F1 · shares: Transaction represents a gift from Dr. Doogan to fund the Declan Doogan 2021 GRAT DTD 03-04-2021 (the "Trust"). Dr. Doogan's wife, Dorothy Doogan, is the trustee of the Trust. Per the terms of the Trust, during its term the Trust must make annuity payments to Dr. Doogan which will be accomplished by transferring shares of common stock back to Dr. Doogan Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionSeries B Preferred Stock · Derivative | 3,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-006925 · section16.xml · derivative · entry 3 Doogan Declan · CIK 0001704234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,070,000 shares Expires 2021-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021. F2 · derivative.exercise_price: As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. F2 · price: As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionCommon Stock | 3,070,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-006925 · section16.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,637,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021. F2 · price: As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. Read SEC document |
| June 10, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001654954-21-006925 · section16.xml · derivative · entry 2 Doogan Declan · CIK 0001704234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2031-06-10 Read SEC document |
| May 21, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 20,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 21 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dorothy Doogan Revocable Trust Disclosed balance after: 0 Read SEC document |
| May 21, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | OtherCommon Shares | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 20 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dorothy Doogan 2020 Trust Disclosed balance after: 187,660 Read SEC document |
| May 21, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 20,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 19 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 129,237 Read SEC document |
| May 21, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | OtherCommon Shares | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 18 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 108,437 Read SEC document |
| May 18, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 31,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 17 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dorothy Doogan Revocable Trust Disclosed balance after: 20,800 Read SEC document |
| May 18, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 20,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 16 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dorothy Doogan Revocable Trust Disclosed balance after: 52,340 Read SEC document |
| May 18, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 20,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 15 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dorothy Doogan 2020 Trust Disclosed balance after: 17,660 Read SEC document |
| May 18, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 31,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 14 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 278,437 Read SEC document |
| May 18, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 113,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 13 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 246,897 Read SEC document |
| May 18, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 113,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 12 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,735 Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:34 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 11,996 | $0.00 Strike: $71.94 | $0.00 |
DisclosureSEC source: 0001562180-21-003336 · primarydocument.xml · derivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,996 Underlying: Common Shares · 11,996 shares Expires 2031-05-04 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2022 or (b) the date of the 2022 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| March 24, 2021 Filed Feb 11, 2022 21:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GiftCommon Shares | 132,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 11 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Declan Doogan Revocable Trust Disclosed balance after: 132,985 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.